FXR agonists improve cholestasis in experimental animals [73], by stimulating hepatocellular BA efflux via induction of BSEP and basolateral overflow systems (via OSTα/β, while lowering endogenous BA synthesis and hepatic BA uptake. The gene discussed is ABCB11; the disease is cholestasis.